HRGN (Harvard Apparatus Regenerative Technology) Beneish M-Score: -6.45 (As of Jun. 26, 2026)


HRGN Harvard Apparatus Regenerative Technology Inc HRGN
34 GF Score
Price $1.39
GF Value $5.34
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Harvard Apparatus Regenerative Technology Beneish M-Score?

Harvard Apparatus Regenerative Technology HRGN 34 Beneish M-Score is -6.45 as of Jun. 26, 2026. GuruFocus rates HRGN with a GF Score™ of 34/100 and a GF Value™ of $5.34 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,849 Consumer Packaged Goods companies, Harvard Apparatus Regenerative Technology ranks better than 98.27% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -6.45 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Harvard Apparatus Regenerative Technology's Beneish M-Score or its related term are showing as below:

HRGN' s Beneish M-Score Range Over the Past 10 Years
Min: -6.5   Med: -3.35   Max: 9.72
Current: -6.45

During the past 13 years, the highest Beneish M-Score of Harvard Apparatus Regenerative Technology was 9.72. The lowest was -6.50. And the median was -3.35.


Harvard Apparatus Regenerative Technology Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Harvard Apparatus Regenerative Technology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Apparatus Regenerative Technology Beneish M-Score Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 9.72 -6.50

Harvard Apparatus Regenerative Technology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.51 -3.35 -3.28 -6.50 -6.45

HRGN vs DTEAF, WYGC, BFNH: Beneish M-Score Comparison

For the Packaged Foods subindustry, Harvard Apparatus Regenerative Technology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Apparatus Regenerative Technology Beneish M-Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Harvard Apparatus Regenerative Technology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's Beneish M-Score falls into.


HRGN
34GF Score
Harvard Apparatus Regenerative Technology Inc HRGN
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Apparatus Regenerative Technology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Harvard Apparatus Regenerative Technology for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.8893+0.528 * 4.0741+0.404 * 1.7126+0.892 * 2.1172+0.115 * 0.9555
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.3741+4.679 * -1.571746-0.327 * 2.3703
=-6.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $0.02 Mil.
Revenue was 0.226 + 0.219 + 0.123 + 0.317 = $0.89 Mil.
Gross Profit was 0.02 + 0.02 + 0.011 + 0.015 = $0.07 Mil.
Total Current Assets was $0.87 Mil.
Total Assets was $1.80 Mil.
Property, Plant and Equipment(Net PPE) was $0.17 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.11 Mil.
Selling, General, & Admin. Expense(SGA) was $4.30 Mil.
Total Current Liabilities was $1.65 Mil.
Long-Term Debt & Capital Lease Obligation was $0.06 Mil.
Net Income was -1.601 + -1.687 + -1.7 + -1.823 = $-6.81 Mil.
Non Operating Income was 0.005 + 0.006 + 0.005 + 0.006 = $0.02 Mil.
Cash Flow from Operations was -0.937 + -0.664 + -1.465 + -0.941 = $-4.01 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0.045 + 0.258 + 0.059 + 0.056 = $0.42 Mil.
Gross Profit was 0.012 + 0.083 + -0.011 + 0.043 = $0.13 Mil.
Total Current Assets was $2.30 Mil.
Total Assets was $3.42 Mil.
Property, Plant and Equipment(Net PPE) was $0.28 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.16 Mil.
Selling, General, & Admin. Expense(SGA) was $5.43 Mil.
Total Current Liabilities was $1.20 Mil.
Long-Term Debt & Capital Lease Obligation was $0.17 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.016 / 0.885) / (0.004 / 0.418)
=0.018079 / 0.009569
=1.8893

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.127 / 0.418) / (0.066 / 0.885)
=0.303828 / 0.074576
=4.0741

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.873 + 0.173) / 1.798) / (1 - (2.302 + 0.279) / 3.415)
=0.418242 / 0.244217
=1.7126

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.885 / 0.418
=2.1172

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.159 / (0.159 + 0.279)) / (0.106 / (0.106 + 0.173))
=0.363014 / 0.379928
=0.9555

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(4.302 / 0.885) / (5.431 / 0.418)
=4.861017 / 12.992823
=0.3741

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.055 + 1.651) / 1.798) / ((0.172 + 1.195) / 3.415)
=0.948832 / 0.400293
=2.3703

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-6.811 - 0.022 - -4.007) / 1.798
=-1.571746

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Harvard Apparatus Regenerative Technology has a M-score of -6.45 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -6.45 mean?
Harvard Apparatus Regenerative Technology (HRGN) has a Beneish M-Score of -6.45 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Harvard Apparatus Regenerative Technology and its competitors. According to the industry distribution chart, Harvard Apparatus Regenerative Technology ranks #32 out of 1849 companies in the Consumer Packaged Goods industry, placing it in the top 1.7%.
Is Harvard Apparatus Regenerative Technology's Beneish M-Score too high?
Harvard Apparatus Regenerative Technology's current Beneish M-Score is -6.45. Based on the distribution chart, Harvard Apparatus Regenerative Technology ranks #32 out of 1849 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Apparatus Regenerative Technology's Beneish M-Score compare to DTEAF and WYGC?
According to the Consumer Packaged Goods industry distribution chart, Harvard Apparatus Regenerative Technology ranks #32 out of 1849 companies for Beneish M-Score. This places Harvard Apparatus Regenerative Technology in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Consumer Packaged Goods company?
A good Beneish M-Score depends on the Consumer Packaged Goods industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Harvard Apparatus Regenerative Technology and its competitors. Harvard Apparatus Regenerative Technology's current Beneish M-Score is -6.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Apparatus Regenerative Technology stock overvalued right now?
Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology (HRGN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.34, compared to a current price of $1.39 — trading 74% below its estimated fair value. The current Beneish M-Score is -6.45. Harvard Apparatus Regenerative Technology's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current Beneish M-Score is -6.45 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Apparatus Regenerative Technology (HRGN) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology stock appears to be undervalued. The current stock price of $1.39 is trading 74% below its estimated GF Value™ of $5.34. GuruFocus considers Harvard Apparatus Regenerative Technology to be Possible Value Trap.

Key valuation signals for HRGN:

  • Beneish M-Score: -6.45
  • GF Value™: $5.34 vs. price of $1.39 (74% below fair value)
  • GF Score™: 34/100 with 2 warning signs

No single metric tells the full story. See the HRGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harvard Apparatus Regenerative Technology Business Description

Address 84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.
34GF Score

Get the complete analysis for HRGN

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$5.34
GF Value